Last update 21 Nov 2024
GST-HG141
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Mechanism HBV core protein modulators, cccDNA inhibitors(cccDNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with GST-HG141GST-HG141治疗经乙肝抗病毒药物治疗的低病毒血症慢性乙型肝炎（CHB）的随机、双盲、安慰剂对照、多中心Ⅱ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial of GST-HG141 in the treatment of low-viremia chronic hepatitis B (CHB) treated with hepatitis B antiviral drugs
A Randomized, Double-blind, Placebo-controlled and Multicenter Phase Ⅱ Clinical Trials To Evaluate the Safety, Efficacy and Pharmacokinetics of GST-HG141 Tablets in Treated Chronic Hepatitis B (CHB) Patients With Low Viremia
评价GST-HG141片在慢性乙型肝炎患者中多中心、随机、
双盲、安慰剂对照的多剂量、多次给药的耐受性、
药效学和药代动力学研究
[Translation] To evaluate the tolerability, pharmacodynamics and pharmacokinetic study of GST-HG141 tablets in patients with chronic hepatitis B in a multicenter, randomized, double-blind, placebo-controlled, multi-dose, multiple-dose
100 Clinical Results associated with GST-HG141
Login to view more data
100 Translational Medicine associated with GST-HG141
Login to view more data
100 Patents (Medical) associated with GST-HG141
Login to view more data
1
Literatures (Medical) associated with GST-HG14117 Sep 2021Antimicrobial Agents and ChemotherapyQ2 · MEDICINE
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial
Q2 · MEDICINE
Article
Author: Wu, Min ; Wu, Wenqiang ; Zhang, Hong ; Tang, Yanan ; Yan, Wenhao ; Mai, Jiajia ; Niu, Junqi ; Li, Cuiyun ; Yang, Lizhi ; Ding, Yanhua ; Zhang, Dong ; Mao, John
100 Deals associated with GST-HG141
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis B, Chronic | Phase 2 | CN | 17 Jan 2023 | |
| Complete atrioventricular block | Phase 2 | CN | 23 Nov 2022 | |
| Viremia | Phase 2 | CN | 23 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | erbxkhcvnq(vteavhwnyv) = xppggbduok rwhemjxwzo (owpannmbny ) | Positive | 25 Jun 2022 | |||
erbxkhcvnq(vteavhwnyv) = olkjahwvdd rwhemjxwzo (owpannmbny ) | |||||||
Phase 1 | - | causzamupn(ihuscduxfr) = bycozyuzfl vaaogyxbaq (uoxxbwpvko, 3.65) View more | - | 23 Jun 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free